Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29108779.
- Also identified by DOI 10.1016/j.radonc.2017.10.019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether pretreatment whole-body total lesion glycolysis (TLG<sub>WB</sub>) and metabolic tumor volume (MTV<sub>WB</sub>) are associated with outcomes in patients with esophageal cancer treated with definitive chemoradiotherapy (dCRT). Ninety patients with stage II or III thoracic esophageal cancer who underwent FDG-PET/CT within 45 days before dCRT between 2005 and 2013 were reviewed. MTV and TLG of the primary lesion (MTV<sub>pri</sub> and TLG<sub>pri</sub>) and the sum of MTV and TLG for all lesions (MTV<sub>WB</sub> and TLG<sub>WB</sub>) were calculated. Predictors were analyzed using the Cox proportional hazards model. The median follow-up period was 27.7 months. In multivariate analysis, MTV<sub>WB</sub> > median was an unfavorable predictor for OS (p = 0.027, hazard ratio [HR]: 2.15), LC (p = 0.039, HR: 1.98) and PFS (p = 0.041, HR: 1.96). TLG<sub>WB</sub> > median was an unfavorable predictor for OS (p = 0.019, HR: 2.26), LC (p = 0.015, HR: 2.36) and PFS (p = 0.014, HR: 2.33). SUV<sub>max</sub> was not a predictor, and the HR of TLG<sub>WB</sub> was higher than that of MTV<sub>WB</sub> for OS, LC and PFS in multivariate analysis. TLG<sub>WB</sub> and MTV<sub>WB</sub> are independent predictors in patients with esophageal cancer.
Medical subject headings
- Chemoradiotherapy
- Esophageal Neoplasms
- Glycolysis